RESUMO
BACKGROUND: Some studies have reported the use of 308-nm excimer laser therapy for treating alopecia areata (AA); however, the effectiveness of this therapy on a theoretical basis has not yet been comparatively analyzed. OBJECTIVES: To determine the therapeutic effect of excimer laser therapy on AA. METHODS: One alopecic patch was divided into control and treated sides in 10 patients with AA. Then, 308-nm excimer laser therapy was administered twice a week for 12 weeks. Photograph and phototrichogram analyses were performed. RESULTS: Photographic assessments by both dermatologists and individuals of the general population showed objective improvements after excimer laser therapy. On the treated side, the hair count and hair diameter had statistically increased after treatment. However, only the hair diameter was found to be significantly high in the treated half when it was compared with the control side. CONCLUSION: The 308-nm excimer laser has a therapeutic effect on AA, which is proven by photograph and phototrichogram analysis by a side-by-side comparison.
Assuntos
Alopecia em Áreas/cirurgia , Cabelo/crescimento & desenvolvimento , Lasers de Excimer/uso terapêutico , Adulto , Eritema/etiologia , Feminino , Humanos , Lasers de Excimer/efeitos adversos , Masculino , Pessoa de Meia-Idade , Fotografação , Adulto JovemAssuntos
Antituberculosos/efeitos adversos , Toxidermias/etiologia , Erupções Liquenoides/induzido quimicamente , Mucosa Bucal/efeitos dos fármacos , Pele/efeitos dos fármacos , Tuberculose Pulmonar/tratamento farmacológico , Corticosteroides/uso terapêutico , Toxidermias/diagnóstico , Toxidermias/tratamento farmacológico , Antagonistas dos Receptores Histamínicos/uso terapêutico , Humanos , Erupções Liquenoides/diagnóstico , Erupções Liquenoides/tratamento farmacológico , Masculino , Pessoa de Meia-Idade , Mucosa Bucal/patologia , Pele/patologia , Resultado do Tratamento , Tuberculose Pulmonar/diagnósticoRESUMO
Erlotinib is a small-molecule tyrosine kinase inhibitor (TKI) of the epidermal growth factor receptor (EGFR). Erlotinib has been used primarily to treat non-small cell lung cancer. In addition to its role in tumor cells, EGFR is also an important regulator of growth and differentiation in the skin and hair. Therefore, EGFR-TKIs have been associated with a number of cutaneous side effects including follicular acneiform eruptions, cutaneous xerosis, chronic paronychia, desquamation, seborrheic dermatitis, and hair texture changes. Herein, we report a rare case of a 61-year-old woman who was treated with erlotinib and experienced cicatricial alopecia.
